0.502
-0.04 (-7.19%)
| Previous Close | 0.541 |
| Open | 0.515 |
| Volume | 3,829,139 |
| Avg. Volume (3M) | 9,546,440 |
| Market Cap | 61,789,460 |
| Price / Book | 15.04 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Diluted EPS (TTM) | -0.780 |
| Total Debt/Equity (MRQ) | 56.38% |
| Current Ratio (MRQ) | 0.540 |
| Operating Cash Flow (TTM) | -30.01 M |
| Levered Free Cash Flow (TTM) | -18.54 M |
| Return on Assets (TTM) | -178.72% |
| Return on Equity (TTM) | -916.17% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Reviva Pharmaceuticals Holdings | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 3.0 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 3.5 |
| Technical Oscillators | 2.0 |
| Average | 1.63 |
|
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer’s disease and Parkinson’s disease psychosis and its other drug candidate is RP1208. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 10.30% |
| % Held by Institutions | 20.35% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Persistent Asset Partners Ltd | 30 Sep 2025 | 593,902 |
| Emc Capital Management | 30 Jun 2025 | 128,415 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 7.00 (Benchmark, 1,293.87%) | Not Rated |
| Median | 3.00 (497.37%) | |
| Low | 2.00 (D. Boral Capital, 298.25%) | Buy |
| 2.00 (Chardan Capital, 298.25%) | Buy | |
| Average | 3.75 (646.71%) | |
| Total | 3 Buy, 1 Not Rated | |
| Avg. Price @ Call | 0.458 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| D. Boral Capital | 19 Nov 2025 | 2.00 (298.25%) | Buy | 0.500 |
| 28 Oct 2025 | 2.00 (298.25%) | Buy | 0.580 | |
| HC Wainwright & Co. | 27 Oct 2025 | 4.00 (696.50%) | Buy | 0.590 |
| Chardan Capital | 29 Sep 2025 | 2.00 (298.25%) | Buy | 0.310 |
| Benchmark | 15 Sep 2025 | 7.00 (1,293.87%) | Not Rated | 0.430 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |